What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes? - PACE-CME

What can new glucoselowering SGLTinhibitors add to CV risk management in diabetes

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Would lower than the current ApoB targets be more useful for clinical decision-making?
Would lower than the current ApoB targets be more useful for clinical decision-making?
CSI 2016 ESC
Would lower than the current ApoB targets be more useful for clinical decision-making?
- Seth Shay Martin, MD
To SPRINT or not to SPRINT to a lower blood pressure target?
To SPRINT or not to SPRINT to a lower blood pressure target?
CSI 2016 ESC
To SPRINT or not to SPRINT to a lower blood pressure target?
A minority of FH patients is identified and labeled as such, which impacts treatment
A minority of FH patients is identified and labeled as such, which impacts treatment
CSI 2016 ESC
A minority of FH patients is identified and labeled as such, which impacts treatment
- Prof Kausik Ray
Targeting residual inflammatory risk as a strategy to lower CV risk
Targeting residual inflammatory risk as a strategy to lower CV risk
CSI 2016 ESC
Targeting residual inflammatory risk as a strategy to lower CV risk
- prof. Paul Ridker, MD